Project Portfolio

Project Portfolio

New small RNA biomarker for ischemic stroke risk prediction

A biomarker to predict possible ischemic stroke.

A blood circulating non-invasive biomarker.

A Predictive method of atherosclerosis and stenosis.

Problema per ser solucionat 
Current diagnostic techniques for atherosclerotic disease and stroke prediction are invasive and not sensitive enough for early stages. Thus, there is a need to create a new diagnostic method more sensitive and less invasive to detect the disease.
Aplicacions 

This circulating biomarker can be used to detect vulnerable atherothrombotic plaque in patients with high-grade carotid artery stenosis and to predict the risk of primary and secondary ischemic stroke. This circulating biomarker might be used as a prognostic biomarker to monitor the effectiveness of the best medical treatment and for the occurrence or restenosis. Determination in serum of this biomarker could also be useful for long-term management monitoring and/or outcome prediction after carotid revascularization procedures. Moreover, this circulating biomarker has been recently proposed as a novel prognostic biomarker for non-small cell lung cancer patients receiving chemotherapy.

Estat de tecnologia 
It has been performed a pilot study in human serum samples with successfully results. IP status: A European patent application has been filled and the PCT submission has been requested.
Oportunitat de mercat 
The global acute ischemic stroke diagnosis and treatment market is expected to reach US$1.869 billion before the end of 2020. It is progressing at a CAGR of 6.3% within a forecast period from 2014 to 2020. The market was valued at US $1.225 billion in 2013, according to the findings of a research report released by Transparency Market Research. Based on diagnostic type, this market is segmented into nuclear imaging, cerebral angioplasty, ultrasound, magnetic resonance imaging, computed tomography, and others. Although CT has dominated the global acute ischemic stroke diagnosis and treatment market so far, it is expected to be steadily replaced by the MRI method, owing to higher efficiency and lower costs. The determination of this circulating miRNA may be less technically demanding, more cost-effective and, therefore, be more amenable for wider, highthroughput routine screening of carotid artery disease than duplex ultrasound.
Context 
Stroke is responsible for more than 10% of deaths worldwide and represents one of the leading causes of disability in the developed countries. Atherosclerosis, the main vascular vessel pathology, results from the inflammatory build-up of lipidladden macrophages in the vessel wall. Carotid artery atherosclerosis has become the major highrisk mechanism for the occurrence of ischemic stroke, which represents more than 80% of all cerebrovascular events. Preventive measures have been developed to avoid carotid stenosis, such as surgical plaque removal by carotid endarterectomy (CEA) or endovascular stent placement (CAS), but these are highly invasive. These invasive revascularization procedures are associated with surgery related mortality and morbidity. Moreover, the intervention of asymptomatic patients with >70% carotid estenosis and <10 years of life expectancy is presently highly controversial due to the improvement of the medical treatment. In clinical practice, the degree of carotid artery stenosis and plaque neovascularization evaluated through imaging techniques such as contrastenhanced ultrasound, positron emission tomography/computed tomography (PET/TC), and magnetic resonance is being considered a most important predictor of carotid plaque vulnerability and, consequently, of increased risk of stroke in patients with carotid artery disease. Nevertheless, a major limitation of the present imaging techniques is their application only in advanced stages of atherosclerotic disease. Thus, novel diagnostic markers using minimally invasive approaches are needed for a more specific and sensitive prediction of atherosclerosis load and progression, and particularly, to reliably identify patients with high-risk carotid plaques for early and accurate stroke risk stratification.
Tecnologia 
The authors have identified a cell-free circulating miRNA as a biomarker for vulnerable atherosclerotic plaque identification in patients with highgrade carotid artery stenosis and, consequently, as a prediction biomarker for primary and secondary ischemic stroke risk, particularly in high cardiovascular risk individuals. Moreover, this circulating miRNA is also a prognostic biomarker to monitor the effectiveness of a medical treatment in these patients. This new small RNA biomarker is more sensitive and less invasive as can be accurately detected in circulating blood.
Technology Readiness Level 
TRL 4
Què busquem? 
Codesenvolupament
Acord de llicència
Inventors 
Aran JM (IDIBELL)
Patent No. 
EP16382025.1
Priority Date 
26/06/2017

New small RNA biomarker for ischemic stroke risk prediction

Technology Readiness Level 
Què busquem? 
Codesenvolupament
Acord de llicència
Patent No. 
EP16382025.1
Priority Date 
26/06/2017
Punts destacats 
A biomarker to predict possible ischemic stroke.A blood circulating non-invasive biomarker.A Predictive method of atherosclerosis and stenosis.
Problema per ser solucionat 
Current diagnostic techniques for atherosclerotic disease and stroke prediction are invasive and not sensitive enough for early stages. Thus, there is a need to create a new diagnostic method more sensitive and less invasive to detect the disease.
Aplicacions 

This circulating biomarker can be used to detect vulnerable atherothrombotic plaque in patients with high-grade carotid artery stenosis and to predict the risk of primary and secondary ischemic stroke. This circulating biomarker might be used as a prognostic biomarker to monitor the effectiveness of the best medical treatment and for the occurrence or restenosis. Determination in serum of this biomarker could also be useful for long-term management monitoring and/or outcome prediction after carotid revascularization procedures. Moreover, this circulating biomarker has been recently proposed as a novel prognostic biomarker for non-small cell lung cancer patients receiving chemotherapy.

Estat de tecnologia 
It has been performed a pilot study in human serum samples with successfully results. IP status: A European patent application has been filled and the PCT submission has been requested.
Oportunitat de mercat 
The global acute ischemic stroke diagnosis and treatment market is expected to reach US$1.869 billion before the end of 2020. It is progressing at a CAGR of 6.3% within a forecast period from 2014 to 2020. The market was valued at US $1.225 billion in 2013, according to the findings of a research report released by Transparency Market Research. Based on diagnostic type, this market is segmented into nuclear imaging, cerebral angioplasty, ultrasound, magnetic resonance imaging, computed tomography, and others. Although CT has dominated the global acute ischemic stroke diagnosis and treatment market so far, it is expected to be steadily replaced by the MRI method, owing to higher efficiency and lower costs. The determination of this circulating miRNA may be less technically demanding, more cost-effective and, therefore, be more amenable for wider, highthroughput routine screening of carotid artery disease than duplex ultrasound.
Context 
Stroke is responsible for more than 10% of deaths worldwide and represents one of the leading causes of disability in the developed countries. Atherosclerosis, the main vascular vessel pathology, results from the inflammatory build-up of lipidladden macrophages in the vessel wall. Carotid artery atherosclerosis has become the major highrisk mechanism for the occurrence of ischemic stroke, which represents more than 80% of all cerebrovascular events. Preventive measures have been developed to avoid carotid stenosis, such as surgical plaque removal by carotid endarterectomy (CEA) or endovascular stent placement (CAS), but these are highly invasive. These invasive revascularization procedures are associated with surgery related mortality and morbidity. Moreover, the intervention of asymptomatic patients with >70% carotid estenosis and <10 years of life expectancy is presently highly controversial due to the improvement of the medical treatment. In clinical practice, the degree of carotid artery stenosis and plaque neovascularization evaluated through imaging techniques such as contrastenhanced ultrasound, positron emission tomography/computed tomography (PET/TC), and magnetic resonance is being considered a most important predictor of carotid plaque vulnerability and, consequently, of increased risk of stroke in patients with carotid artery disease. Nevertheless, a major limitation of the present imaging techniques is their application only in advanced stages of atherosclerotic disease. Thus, novel diagnostic markers using minimally invasive approaches are needed for a more specific and sensitive prediction of atherosclerosis load and progression, and particularly, to reliably identify patients with high-risk carotid plaques for early and accurate stroke risk stratification.
Tecnologia 
The authors have identified a cell-free circulating miRNA as a biomarker for vulnerable atherosclerotic plaque identification in patients with highgrade carotid artery stenosis and, consequently, as a prediction biomarker for primary and secondary ischemic stroke risk, particularly in high cardiovascular risk individuals. Moreover, this circulating miRNA is also a prognostic biomarker to monitor the effectiveness of a medical treatment in these patients. This new small RNA biomarker is more sensitive and less invasive as can be accurately detected in circulating blood.